JMD Bill & Melinda Gates Foundation
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow Open Choice Article
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Iverson, A. A.
Right arrow Articles by Chang, S.-Y. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iverson, A. A.
Right arrow Articles by Chang, S.-Y. P.
Journal of Molecular Diagnostics 2009, Vol. 11, No. 2
Copyright © 2009 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2009.080070

A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens

Ayuko A. Iverson*, Cheryl Gillett{dagger}, Paul Cane{dagger}{ddagger}, Christopher D. Santini*, Thomas M. Vess*, Lauren Kam-Morgan§, Alice Wang*, Marcia Eisenberg§, Charles M. Rowland*, Janice J. Hessling§, Samuel E. Broder, John J. Sninsky*, Andrew Tutt||, Steven Anderson§ and Sheng-Yung P. Chang*

From Celera, * Alameda, California; the Breast Pathology Laboratory, {dagger} Guy’s Hospital, London, United Kingdom; the Histopathology Department, {ddagger} St Tomas’ Hospital, London, United Kingdom; the Laboratory Corporation of America, § Research Triangle Park, North Carolina; Celera, Rockville, Maryland; the Breakthrough Breast Cancer Research Unit, || Guy’s Hospital, Kings College, London, United Kingdom

Knowledge of estrogen receptor (ER) and progesterone receptor (PR) status has been critical in the evolution of modern targeted therapy of breast cancer and remains essential for making informed therapeutic decisions. Recently, growth factor receptor HER2/neu (ERBB2) status has made it possible to provide another form of targeted therapy linked to the overexpression of this protein. Presently, pathologists determine the receptor status in formalin-fixed, paraffin-embedded sections using subjective, semiquantitative immunohistochemistry (IHC) assays and quantitative fluorescence in situ hybridization for HER2. We developed a single-tube multiplex TaqMan (mERPR+HER2) assay to quantitate mRNA levels of ER, PR, HER2, and two housekeeping genes for breast cancer formalin-fixed, paraffin-embedded sections. Using data from the discovery sample sets, we evaluated IHC-status-dependent cutoff-point and IHC-status-independent clustering methods for the classification of receptor status and then validated these results with independent sample sets. Compared with IHC-status, the accuracies of the mERPR+HER2 assay with the cutoff-point classification method were 0.98 (95% CI: 0.97–1.00), 0.92 (95% CI: 0.88–0.95), and 0.97 (95% CI: 0.95–0.99) for ER, PR, and HER2, respectively, for the validation sets. Furthermore, the areas under the receiver operating-characteristic curves were 0.997 (95% CI: 0.994–1.000), 0.967 (95% CI: 0.949–0.985), and 0.968 (95% CI: 0.915–1.000) for ER, PR, and HER2, respectively. This multiplex assay provides a sensitive and reliable method to quantitate hormonal and growth factor receptors.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Society for Investigative Pathology and the Association for Molecular Pathology.